---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-027510"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:09:43.497547+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma reports Q4 2023 GAAP net loss $8.5M; non-GAAP net profit $1.4M; YUPELRI net sales up 9% to $60.6M

## Summary
- Q4 YUPELRI net sales recognized by Viatris grew 9% YoY to $60.6M record high; full-year Viatris collaboration revenue up 18% to $57.2M.
- GAAP net loss of $8.5M in Q4; achieved non-GAAP net profit of $1.4M, driven by YUPELRI growth and expense management.
- Completed $325M capital return program early Jan 2024, reducing shares outstanding by 37%.
- YUPELRI hospital volumes grew 46% YoY, exceeding targets; CYPRESS study enrollment on track for H2 2024.
- Ampreloxetine granted FDA Orphan Drug Designation; investor event planned for Q2 2024.

## SEC filing metadata
- accession: 0001104659-24-027510
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/0001104659-24-027510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/tm247202d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-027510
- JSON: https://secwatch.observer/filing/0001104659-24-027510.json
- Plain text: https://secwatch.observer/filing/0001104659-24-027510.txt

## Key facts
- Earnings Releases
  Theravance Biopharma, Inc. reported full year ended December 31, 2023 results: revenue $57.2 million.
  - Period: full year ended December 31, 2023
  - Revenue: $57.2 million
  - Result: reported results
  source text: · Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/0001104659-24-027510-index.htm
- Earnings Releases
  Theravance Biopharma, Inc. reported Q4 2023 results: net income $8.5 million.
  - Period: Q4 2023
  - Net income: $8.5 million
  - Result: reported results
  source text: · GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million 2
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/0001104659-24-027510-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.